Phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (pac) in patients (pts) with DKK1+relapsed or refractory esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).

被引：9
|
作者：
Bendell, Johanna C.
Murphy, Janet E.
Mahalingam, Devalingam
Halmos, Balazs
Sirard, Cynthia A.
Landau, Steven B.
Ryan, David P.
机构：
[1] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
[4] Columbia Univ, Med Ctr, New York, NY USA
[5] HeathCare Pharmaceut Inc, Cambridge, MA USA
[6] Healthcare Ventures, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.111
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
111
引用
收藏
页数：1
相关论文
共 17 条
  • [1] Current results of a phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (P) in patients (pts) with advanced DKK1+esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).
    Ryan, David P.
    Murphy, Janet E.
    Mahalingam, Devalingam
    Halmos, Balazs
    Sirard, Cynthia A.
    Landau, Steven B.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)
    Ryan, D. P.
    Murphy, J.
    Mahalingam, D.
    Strickler, J.
    Stein, S.
    Sirard, C.
    Landau, S.
    Bendell, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 108 - 108
  • [3] The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer
    Wall, Jaclyn A.
    Klempner, Samuel J.
    Arend, Rebecca C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (07) : 639 - 644
  • [4] Phase I study of DKN-01 I an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer.
    Eads, Jennifer Rachel
    Goyal, Lipika
    Stein, Stacey
    El-Khoueiry, Anthony B.
    Manji, Gulam A.
    Abrams, Thomas Adam
    Landau, Steven B.
    Sirard, Cynthia A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC)
    Eads, J.
    Stein, S.
    El-Khoueiry, A.
    Manji, G.
    Abrams, T.
    Khorana, A. A.
    Miksad, R.
    Mahalingam, D.
    Sirard, C.
    Zhu, A. X.
    Goyal, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers
    Klempner, Samuel J.
    Bendell, Johanna C.
    Villaflor, Victoria Meucci
    Tenner, Laura LaNiel
    Stein, Stacey M.
    Rottman, James B.
    Naik, Girish S.
    Sirard, Cynthia A.
    Kagey, Michael H.
    Chaney, Marya F.
    Strickler, John H.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (11) : 2240 - 2249
  • [7] A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC).
    Eads, Jennifer Rachel
    Stein, Stacey
    El-Khoueiry, Anthony B.
    Manji, Gulam Abbas
    Abrams, Thomas Adam
    Khorana, Alok A.
    Miksad, Rebecca A.
    Mahalingam, Devalingam
    Sirard, Cynthia A.
    Zhu, Andrew X.
    Goyal, Lipika
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Potential biomarkers of response to DKK1 blockade with DKN-01 in combination with paclitaxel in advanced esophagogastric cancer (EGC) patients (pts)
    Duda, D. G.
    Sirard, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/ gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase study
    Liu, J. J.
    Yu, X.
    Zhang, J.
    Yang, J.
    Yue, J.
    Sun, Y.
    Pan, Y.
    Sun, M.
    Qin, Y.
    Shen, L.
    Song, R.
    Ruan, J.
    Zhou, A.
    Mou, Y.
    Liu, Z.
    Liu, Z.
    Morris, M.
    Aghmesheh, M.
    Tazbirkova, A.
    Zhou, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S160 - S160
  • [10] A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx)
    Padmanabhan, Swaminathan
    Beck, Joseph Thaddeus
    Kelly, Kevin R.
    Munshi, Nikhil C.
    Dzik-Jurasz, Andy
    Gangolli, Esha
    Ettenberg, Seth
    Miner, Kelly
    Bilic, Sanela
    Whyte, Winston
    Mehdi, Fazal
    Chiang, Lu-May
    Rae, Patricia Liz
    Spencer, Andrew
    Shah, Jatin
    Anderson, Kenneth C.
    Giles, Francis J.
    Stewart, A. Keith
    BLOOD, 2009, 114 (22) : 312 - 313
12